【レポートの概要（一部）】
1. Report Summary
1.1 Leading Contract Manufacturing Organisations (CMOs) Review
1.2 Leading CMOs – Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers Information
1.5 Main Questions This Report Answers
1.6 Who is This Report For?
1.7 Methods of Research and Analysis
1.8 Frequently Asked Questions (FAQs)
1.9 Some Related Reports
1.10 About Visiongain
2. Introduction to Pharmaceutical Contract Manufacturing, 2014
2.1 What Services Do Contract Manufacturers Offer?
2.1.1 Why Do Firms Outsource Manufacturing?
2.1.2 What Is Driving Demand for Contract Manufacturing Services?
2.2 The Pharmaceutical Contract Manufacturing Market, 2013
2.2.1 Where is Supply and Demand Highest for Contract Manufacturing Services?
2.3 Outlook for the Pharmaceutical Contract Manufacturing Market 2014-2024
2.4 Driving and Restrictive Forces for Pharmaceutical Contract Manufacturing, 2014-2024
2.4.1 Pharmaceutical Contract Manufacturing: Market Drivers 2014-2024
2.4.2 Pharmaceutical Contract Manufacturing: Market Restraints 2014-2024
2.5 Who Are the Leading Pharmaceutical Contract Manufacturers in 2014?
3. Leading European Contract Manufacturing Organisations (CMOs), 2014
3.1 Lonza
3.1.1 Lonza Is a Leader in Biologics Manufacturing
3.1.2 Lonza Contract Manufacturing and Development: Declining Revenue, but Increased Efficiency, 2009-2013
3.1.3 Investing in Advanced Biological Drug Sectors
3.1.4 The Promise of Antibody-Drug Conjugates (ADCs)
3.1.5 Lonza and Regenerative Medicine
3.1.6 Lonza: SWOT Analysis 2014-2024
3.1.7 Biologics and Efficiency Savings Will Drive Growth in Revenue and Operating Profit for Lonza 2014-2024
3.1.8 Lonza: Company Insight
3.2 Evonik Degussa
3.2.1 Investing in API and Drug Delivery Services
3.2.2 Moderate Growth in Pharmaceutical Manufacturing Services, 2009-2013
3.2.3 Evonik Is a HPAPI Specialist
3.2.4 Evonik Continues to Grow Across All Segments
3.2.5 How Can Evonik Expand in the Pharmaceutical Contract Manufacturing Market?
3.2.6 Evonik Degussa: Revenue Forecast 2014-2024
3.3 Royal DSM
3.3.1 Marginal Revenue Growth and Rapidly Declining Operating Profit in Pharma Manufacturing 2009-2013
3.3.2 DSM Pharmaceuticals Products: Manufacturing Services 2009-2013
3.3.3 DSM Sinochem Pharmaceuticals: A World Leader in Antibacterial Manufacturing
3.3.4 DPx Holdings: A New Leader in the CMO Market
3.3.5 Investing in Biopharma Manufacturing
3.3.6 Expanding API Manufacturing
3.3.7 Generics and Biologics Are an Opportunity for Growth, 2014-2024
3.3.8 DSM Pharmaceuticals Products: Revenue Forecast 2014-2024
3.4 Boehringer Ingelheim Contract Manufacturing
3.4.1 Expanding Biopharmaceuticals Manufacturing Services in China
3.4.2 Production Through to Fill and Finished Biopharmaceuticals
3.4.3 A Track Record of Production for 28 Biopharma Products
3.4.4 Declining Revenue from Contract Manufacturing, 2009-2013
3.4.5 Pulling Out of Small Molecule API Manufacturing
3.4.6 Expanding through New Services
3.4.7 Boehringer Ingelheim Biopharmaceuticals: Opportunities for Growth 2014-2024
3.4.8 Boehringer Ingelheim: Revenue Forecast 2014-2024
3.4.9 Boehringer Ingelheim Biopharmaceuticals: Company Insight
3.5 Fareva
3.5.1 Fareva Has 35 Years’ Manufacturing Experience
3.5.2 Revenue Growth through Acquisitions: 2009-2013
3.5.3 Fareva SWOT Analysis: 2014-2024
3.5.4 Fareva Revenue Forecast: 2014-2024
3.6 Aenova Group
3.6.1 Acquisition of Haupt Creates European CMO Goliath
3.6.2 Aenova’s Ever Expanding Manufacturing Capacity
3.6.3 Aenova’s Revenue 2009-2013: Organic Growth and Acquisitions
3.6.4 Haupt Pharma Acquisition: Revenue Growth 2009-2013
3.6.5 Aenova’s Competitive Position in the Contract Manufacturing Market: SWOT Analysis 2014-2024
3.6.6 Becoming a Leading Contract Manufacturer: Aenova Revenue and Operation Profit Forecast 2014-2024
3.7 Famar
3.7.1 Famar Is an Expert in Lyophilisation
3.7.2 Sustained Growth in Famar’s Revenue: 2009-2013
3.7.3 Expanding European Operations
3.7.4 Further Site Acquisitions Are an Opportunity for Growth 2014-2024
3.7.5 How Will Famar Perform 2014-2024?
3.8 Vetter Pharma
3.8.1 Vetter is an Injectable Manufacturing Specialist
3.8.2 Rapidly Growing Revenue in the US and Germany: 2009-2013
3.8.3 Services, Collaborations and Differentiating Factors
3.8.4 Biologics Are an Opportunity for Growth for Vetter 2014-2024
3.8.5 Vetter Outlook: Revenue Forecast 2014-2024
3.9 Almac Group
3.9.1 Almac’s Manufacturing Services
3.9.2 Almac Outpaces the Market: 2009-2013
3.9.3 Almac Adds Capacity in the UK and US
3.9.4 New Services Added 2012-2014
3.9.5 Almac Group: Contract Manufacturing Market Outlook 2014-2024
3.9.6 How Will Almac Group Perform 2014-2024?
3.10 Delpharm
3.10.1 Finished Dosage Form Manufacturing for Developed Markets
3.10.2 Delpharm: Rapid Revenue Growth Via Acquisitions, 2009-2013
3.10.3 Delpharm: Outlook and Prospects for Growth 2014-2024
3.10.4 Generics Will Drive Revenue Growth for Delpharm 2014-2024
3.11 Siegfried
3.11.1 Expanding Siegfried’s Manufacturing Footprint
3.11.2 Siegfried: Financial Performance 2009-2013
3.11.3 Expanding High Potency API Capabilities
3.11.4 Expanding Into China 2013-2014
3.11.5 Siegfried’s Characteristics Within the Contract Manufacturing Market: SWOT Analysis 2014-2024
3.11.6 Continued Revenue Growth for Siegfried 2014-2024
3.12 Corden Pharmaceutical
3.12.1 CordenPharma Has Grown through Acquisitions
3.12.2 Corden Pharmaceutical: SWOT Analysis 2014-2024
3.13 Recipharm
3.13.1 Contract Development and Manufacturing Services
3.13.2 Recipharm: Financial Performance 2009-2013
3.13.3 Recipharm Invests in Facility Expansion
3.13.4 Recipharm: Opportunities for Growth 2014-2024
3.13.5 Outlook for Recipharm: Revenue Forecast 2014-2024
3.13.6 Recipharm: Company Insight
3.14 Aesica Pharmaceuticals
3.14.1 Aesica Manufactures APIs and Finished Dosage Forms
3.14.2 Acquisitions Drive Revenue Growth But Operational Margins Have Declined, 2009-2013
3.14.3 Partnering with Academia for Innovative Solutions
3.14.4 Growth through Acquisitions and Internal Expansion
3.14.5 Aesica: Opportunities for Expansion 2014-2024
3.14.6 Forecast Aesica Financial Performance, 2014-2024
4. Other Leading Developed-Market CMOs, 2014
4.1 Catalent Pharma Solutions Is the World’s Largest CMO
4.1.1 Catalent: Manufacturing Services and Capabilities
4.1.2 Divisional Segmentation – Breaking Down Catalent’s Service
4.1.3 Revenue Growth with Improved Operational Margins: Catalent Pharma’s Performance, 2009-2013
4.1.4 Sustained Grow in Oral Products and Development Services: Catalent Pharma’s Divisional Performance, 2009-2013
4.1.5 Catalent Is Expanding its Oral Technologies Division
4.1.6 Quadrupling Biopharmaceutical Manufacturing Capacity
4.1.7 Adding New Early-Stage Development Services
4.1.8 Expansion in Japan – Growth Prospects for Catalent
4.1.9 New Business Contracts 2013-2014
4.1.10 Catalent: Opportunities for Growth 2014-2024
4.1.11 Catalent: Mild Growth in Revenue and Operating Profit 2014-2024
4.2 Patheon – FDF Manufacturer and Drug Development Services
4.2.1 Patheon – Global leader in Pharmaceutical Development Services
4.2.2 Contract Manufacturing Services at Patheon
4.2.3 Steady Revenue Growth 2009-2013
4.2.4 Formation of DPx Holdings
4.2.5 Adding New Formulations and Formulation Development Services
4.2.6 Reassessing Manufacturing Capacity
4.2.7 Patheon: SWOT Analysis 2014-2024
4.2.8 Patheon: Contract Manufacturing Revenue Forecast 2014-2024
4.2.9 Patheon: Company Insight
4.3 Baxter BioPharma Solutions
4.3.1 Baxter BioPharma is the Global Leader in Sterile Fill and Finish
4.3.2 Historic Revenue Performance 2009-2013
4.3.3 Baxter BioPharma SWOT Analysis 2014-2024
4.3.4 Baxter BioPharma Revenue Forecast 2014-2024
4.4 Nipro Corporation: Japan’s Leading CMO
4.4.1 Nipro Pharmaceutical Contract Manufacturing Capabilities
4.4.2 Nipro: Exceptional Growth in Revenue and Operating Profits 2009-2013
4.4.3 Biosimilars and Anti-Cancer Drugs Are Opportunities for Future Growth: SWOT Analysis 2014-2024
4.4.4 Nipro Revenue and Profitability Forecast 2014-2014
4.5 AbbVie Contract Manufacturing
4.5.1 AbbVie Offers Full-Service Contract Manufacturing
4.5.2 Expanding and Adding New Services: 2013-2014
4.5.3 AbbVie Contract Manufacturing: Revenue 2011-2013
4.5.4 Biologics and HPAPIs Are an Opportunity for Growth 2014-2024
4.5.5 AbbVie Contract Manufacturing Revenue Forecast 2014-2024
4.5.6 AbbVie Contract Manufacturing: Company Insight
4.6 Daito Pharmaceutical
4.6.1 Daito Has a Portfolio of More than 30 APIs
4.6.2 Rapid Growth in Revenue and Operational Profit: Daito Financial Performance 2009-2013
4.6.3 Daito Is Well-Placed for Asian Market Growth – SWOT Analysis 2014-2024
4.6.4 Sustained Growth in Revenue and Operating Profit for Daito, 2014-2024
4.7 Pfizer CentreSource
4.7.1 Pfizer CentreSource: Historic Revenue Performance, 2009-2013
4.7.2 Will Pfizer Divest CentreSource?
4.7.3 Outlook for CentreSource: Revenue Forecast 2014-2024
5. Leading Developed Market API Manufacturers, 2014
5.1 Teva API
5.1.1 API Manufacturing Services
5.1.2 Teva API: Financial Performance 2009-2013
5.1.3 Building a Footprint in Mexico, India and China
5.1.4 Teva API: SWOT Analysis 2014-2024
5.1.5 Outlook for Teva API: Revenue Forecast 2014-2024
5.2 Esteve Química
5.2.1 Esteve Química Manufactures APIs for Developed and Emerging Markets
5.2.2 Investing to Expand 2004-2013
5.2.3 Esteve Química: SWOT Analysis 2014-2024
5.3 Euticals
5.3.1 Euticals Manufactures More than 200 APIs
5.3.2 Acquisitions Drive Growth 2009-2013
5.3.3 Adding Capacity for Finished Dosage Forms
5.3.4 Asian Expansion Is an Opportunity for Growth 2014-2024
5.3.5 Euticals: Revenue Forecast 2014-2024
6. Leading Chinese Pharmaceutical Contract Manufacturers, 2014
6.1 Zhejiang Hisun Pharmaceutical
6.1.1 API Manufacturing for Markets Worldwide
6.1.2 Zhejiang Hisun’s Rapid Growth in API Revenue Grows, 2009-2013
6.1.3 Moving Into International Drug Marketing
6.1.4 Zhejiang Hisun: Opportunities for Growth 2014-2024
6.1.5 Zhejiang Hisun: Strong API Revenue Growth 2014-2024
6.2 Zhejiang Huahai Pharmaceuticals
6.2.1 Zhejiang Huahai Is a Market Leader Within the Antihypertensive API Market
6.2.2 Zhejiang Huahai: Contract Manufacturing Performance 2009-2013
6.2.3 Expanding in the US Generic Drugs Market
6.2.4 Zhejiang Huahai: SWOT Analysis, 2014
6.2.5 Zhejiang Huahai: Revenue Forecast, 2014-2024
6.3 Shandong Xinhua Pharmaceutical
6.3.1 Experience in APIs and Finished Dosage Forms
6.3.2 Shandong Xinhua: Strong Revenue Growth 2009-2013
6.3.3 Growing through Joint Ventures
6.3.4 Looking to Expand in the US and EU 2014-2024
6.3.5 Shandong Xinhua Pharmaceutical: Revenue Forecast 2014-2024
7. Leading Indian Pharmaceutical Contract Manufacturers, 2014
7.1 Aurobindo Pharma
7.1.1 API Manufacturing Services
7.1.2 Aurobindo Pharma: Steady Revenue Growth 2009-2013
7.1.3 Aurobindo Expanding Outside of Antibacterials
7.1.4 Aurobindo: Opportunities for Expansion 2014-2024
7.1.5 How Will Aurobindo’s Contract Manufacturing Division Perform 2014-2024?
7.2 Divis Laboratories
7.2.1 Divis Laboratories and the Contract Manufacturing Industry
7.2.2 Divis Laboratories: The Fastest Growing CMO 2009-2013
7.2.3 Divis Laboratories: API Manufacturing Outlook 2014-2024
7.2.4 Divis Laboratories: API Manufacturing Revenue Forecast, 2014-2024
7.3 Dr. Reddy’s Laboratories
7.3.1 API and FDF Manufacturing Services
7.3.2 Dr. Reddy’s PSAI: Strong Revenue Growth 2009-2013
7.3.3 Advancing in Complex Drug Manufacturing
7.3.4 Expanding in the European Manufacturing Market
7.3.5 Dr. Reddy’s PSAI Division: Revenue Forecast 2014-2024
8. Conclusions to Our Study
8.1 What Has Driven Growth for CMO Market Leaders in Recent Years?
8.2 Strategies for Growth: Prospects for Leading CMOs, 2014-2024
8.3 High Demand for Biopharmaceutical Manufacturing Services
8.4 Investing in Novel Technologies
8.5 Outlook for API Manufacturers
【レポート販売概要】
■ タイトル：医薬品有力企業シリーズ：主要医薬品製造受託機関(CMO)分析■ 英文：Pharma Leader Series : Leading Pharmaceutical Contract Manufacturing Organisations (CMOs) 2014-2024
■ 発行日：2014年9月
■ 調査会社：visiongain
■ 商品コード：VISION411062
■ 調査対象地域：グローバル
- 薄膜太陽電池モジュール市場2013Thin-film Solar Module Market Analysis, 2013 - First Solar, the Undisputed Leader Summary Global thin-film solar module production capacity grew at a CAGR of 29% from 1,858 MW in 2008 to 6,568 MW by the year end 2013. However, demand for thin-film solar modules did not surge as significantly as the growth in thin-film module production capacity which resulted in higher overcapacity rate of 105% in …
- 中国のデータセンター市場2016-2020About Data Center Data centers are established by either large-scale enterprises or enterprises offering cloud-based services. Enterprises are building colocation and managed hosting data center facilities and renting them to other large enterprises and SMEs. With the evolution of cloud computing and increased use of big data analytics, more data centers that can cater to the increased computing r …
- Poplar Creek Resources, Inc.：石油・ガスの開発・生産動向及びコスト分析- Q3, 2013Poplar Creek Resources, Inc. Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2013 Summary Poplar Creek Resources, Inc. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an es …
- 自動車用コネクタの世界市場2016-2020About Automotive Connectors A connector is a device that transmits electric signals either from the power source to the electronic equipment or connects the internal controls of a machine. It forms a medium of communication between different systems and components by connecting electric circuits with each other. Technavio’s analysts forecast the global automotive connectors market to grow at a CAG …
- Mobile Application Marketplace Mobile Applications Stores 2012: Asia – Market Analysis and Business AssessmentThe evolution of the cell phone, driven by the wireless data industry trying to make individuals more productive wherever they are, has led to the current state of the art device, referred to as the Smartphone. Smart phones are nothing more than handheld computers that support email, personal organizers, voice & data communications services and other applications. All smart phones come loaded with …
- 無人機の世界市場：地域別分析Summary This report offers detailed analysis of the global Unmanned Aerial Vehicle market over the next ten years, and provides extensive market size forecasts by country and sub sector. It covers the key technological and market trends in the Unmanned Aerial Vehicle market. Key Findings "The Global Unmanned Aerial Vehicle Market 2015-2025 - Country Analysis: Market Profile" provides details of th …
- Salamander Energy plc：石油・ガスバリューチェーン分析レポート2013Salamander Energy plc Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "Salamander Energy plc" Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “Salamander Energy plc”. The report provides key information relating to oil and gas assets of the company along with its operations across the value chain. The report e …
- 睡眠リズム障害（Circadian Rhythm Sleep Disorders）：グローバル臨床試験動向（2014年上半期）Circadian Rhythm Sleep Disorders Global Clinical Trials Review, H1, 2014 Summary GlobalData's clinical trial report, “Circadian Rhythm Sleep Disorders Global Clinical Trials Review, H1, 2014" provides data on the Circadian Rhythm Sleep Disorders clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Circadian Rhythm Sleep Disorders. It inclu …
- マラリア検査の世界市場2015The report presents a detailed analysis of the Malaria diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Malaria definition, epidemiology and etiology are reviewed. The report provides the 5- and 10-year test volume and sales forecasts by country for the following market segments: - Hospitals - …
- 世界の主要ウェアラブル技術企業動向2014Wearable technology is the buzzword of 2014. A market that has existed for decades, however now microprocessors and MEMS are finally compact enough for the device category to reach fruition. In an environment heading towards a connected homes paradigm, the next step in our technological evolution is bringing control closer than arm’s reach. Wearables dominated 2014’s CES, with every major OEM cham …
- 先進複合材料の世界市場予測（～2022年）：炭素、Sクラス、アラミド、熱硬化性樹脂、熱可塑性樹脂The advanced composites market is projected to grow from an estimated USD 22.91 Billion in 2017 to USD 38.41 Billion by 2022, at a CAGR of 10.89% between 2017 and 2022. The growth of the advanced composites market can be attributed to increased use of advanced composites in the aerospace & defense, sporting goods, and transportation industries, as these offer a high strength-to-weight ratio and in …
- Zebinix (Epilepsy)：市場予測と分析（～2022）Zebinix (Epilepsy) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Zebinix (Epilepsy) - Forecast and Market Analysis to 2022”. Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED …
- バリア樹脂の世界市場予測（～2026年）The global barrier resins market is projected to reach USD 3.52 Billion by 2026, at a CAGR of 5.85% from 2016 to 2026. Growth in the demand for the ethylene vinyl alcohol (EVOH) type is increasing the demand in the global barrier resins market. Rising demand from end-use industries in the developed and emerging countries is driving the growth of the global barrier resins market. In 2015, the food …
- ネットワーク中立性に関するグローバルベンチマークThis report provides an in-depth benchmark of 12 major countries regarding the Net Neutrality debate, taking into account discrimination practices, state of regulatory and political debate, stakeholders positions and provides analysis of case studies.
- C型肝炎ウイルス感染：グローバル治療薬の市場予測と分析PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the mar …
